Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1990 Mar;61(3):429–433. doi: 10.1038/bjc.1990.94

Evidence that multiple myeloma may be regulated by homeostatic control mechanisms: correlation of changes in the number of clonogenic myeloma cells in vitro with clinical response.

J A Maitland 1, B C Millar 1, J B Bell 1, A Montes 1, J Treleaven 1, M E Gore 1, T J McElwain 1
PMCID: PMC1971273  PMID: 2328211

Abstract

Myeloma colonies (MY-CFUc) could be grown in vitro for 6 months (median time) after a group of 12 myeloma patients had reached complete remission (CR). In a second group of 25 patients MY-CFUc increased in 17/25 and GM-CFUc in 20/25 patients after cyclophosphamide even though 24/25 patients had a partial response to VAMP and one was in CR. These data suggest that cell killing by cyclophosphamide stimulates residual tumour cells into proliferation and adds further support to the idea that myeloma is under some degree of homeostatic control which may be analogous to that in normal bone marrow. Although lymphoplasmacytoid myeloma cells may be more drug resistant than plasmacytoid myeloma cells in vitro, it was not possible to conclude that the emergence of lymphoplasmacytoid cells at relapse was indicative of resistance to further treatment.

Full text

PDF
429

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Barlogie B., Smith L., Alexanian R. Effective treatment of advanced multiple myeloma refractory to alkylating agents. N Engl J Med. 1984 May 24;310(21):1353–1356. doi: 10.1056/NEJM198405243102104. [DOI] [PubMed] [Google Scholar]
  2. Bartl R., Frisch B., Fateh-Moghadam A., Kettner G., Jaeger K., Sommerfeld W. Histologic classification and staging of multiple myeloma. A retrospective and prospective study of 674 cases. Am J Clin Pathol. 1987 Mar;87(3):342–355. doi: 10.1093/ajcp/87.3.342. [DOI] [PubMed] [Google Scholar]
  3. Bell J. B., Millar B. C., Maitland J. A., Nandi A., Gore M., McElwain T. J. Increase in clonogenic tumour cells in bone marrow of patients with multiple myeloma treated with vincristine, doxorubicin, and methylprednisolone. Lancet. 1988 Oct 22;2(8617):931–933. doi: 10.1016/s0140-6736(88)92599-8. [DOI] [PubMed] [Google Scholar]
  4. Bonnet J., Alexanian R., Salmon S., Bottomley R., Amare M., Haut A., Dixon D. Vincristine, BCNU, doxorubicin, and prednisone (VBAP) combination in the treatment of relapsing or resistant multiple myeloma: a Southwest Oncology Group study. Cancer Treat Rep. 1982 Jun;66(6):1267–1271. [PubMed] [Google Scholar]
  5. Bradley T. R., Hodgson G. S., Rosendaal M. The effect of oxygen tension on haemopoietic and fibroblast cell proliferation in vitro. J Cell Physiol. 1978 Dec;97(3 Pt 2 Suppl 1):517–522. doi: 10.1002/jcp.1040970327. [DOI] [PubMed] [Google Scholar]
  6. Evans B. D., Smith I. E., Clutterbuck R. D., Millar J. L. Normal tissue toxicity and antitumour experiments carried out in mice using high-dose cyclophosphamide. Cancer Treat Rev. 1983 Sep;10 (Suppl A):25–32. doi: 10.1016/s0305-7372(83)80004-8. [DOI] [PubMed] [Google Scholar]
  7. Gore M. E., Selby P. J., Viner C., Clark P. I., Meldrum M., Millar B., Bell J., Maitland J. A., Milan S., Judson I. R. Intensive treatment of multiple myeloma and criteria for complete remission. Lancet. 1989 Oct 14;2(8668):879–882. doi: 10.1016/s0140-6736(89)91548-1. [DOI] [PubMed] [Google Scholar]
  8. Kyle R. A., Pajak T. F., Henderson E. S., Nawabi I. U., Brunner K., Henry P. H., McIntyre O. R., Holland J. F. Multiple myeloma resistant to melphalan: treatment with doxorubicin, cyclophosphamide, carmustine (BCNU), and prednisone. Cancer Treat Rep. 1982 Mar;66(3):451–456. [PubMed] [Google Scholar]
  9. Millar B. C., Bell J. B., Lakhani A., Ayliffe M. J., Selby P. J., McElwain T. J. A simple method for culturing myeloma cells from human bone marrow aspirates and peripheral blood in vitro. Br J Haematol. 1988 Jun;69(2):197–203. doi: 10.1111/j.1365-2141.1988.tb07622.x. [DOI] [PubMed] [Google Scholar]
  10. Millar B. C., Bell J. B., Maitland J. A., Zuiable A., Gore M. E., Selby P. J., McElwain T. J. In vitro studies of ways to overcome resistance to VAMP--high dose melphalan in the treatment of multiple myeloma. Br J Haematol. 1989 Feb;71(2):213–222. doi: 10.1111/j.1365-2141.1989.tb04257.x. [DOI] [PubMed] [Google Scholar]
  11. Millar J. L., Hudspith B. N., Blackett N. M. Reduced lethality in mice receiving a combined dose of cyclophosphamide and busulphan. Br J Cancer. 1975 Aug;32(2):193–198. doi: 10.1038/bjc.1975.149. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Millar J. L., McElwain T. J. Combinations of cytotoxic agents that have less than expected toxicity on normal tissues in mice. Antibiot Chemother (1971) 1978;23:271–282. doi: 10.1159/000401490. [DOI] [PubMed] [Google Scholar]
  13. Stevenson G. T., Thompson J. Idiotypes and anti-idiotypes in myeloma. Hematol Oncol. 1988 Apr-Jun;6(2):103–106. doi: 10.1002/hon.2900060208. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES